Gufic Biosciences reported a total revenue of ₹252.1 crore for the quarter ended March 31, 2026 (Q4 FY26), marking an increase from ₹205 crore in Q4 FY25. The company achieved a Profit After Tax (PAT) of ₹20.6 crore for the quarter, compared to ₹8 crore in the corresponding period of the previous year. For the full financial year FY26, the company recorded a total revenue of ₹940.5 crore and a PAT of ₹63.2 crore.

Financial Performance

The company's EBITDA for Q4 FY26 stood at ₹45.9 crore, with an EBITDA margin of 18.22%, up from 12.99% in Q4 FY25. The full-year EBITDA for FY26 was ₹152.9 crore. The Indore facility, which commenced production in October 2024, achieved 30% capacity utilization in FY26. The management indicated that at peak utilization (75%+), the Indore facility alone can generate approximately ₹675–700 crore of revenue from domestic and export markets.

The table below summarises the company's key financial metrics across recent quarters and full years:

Operational Updates

The Indore facility is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards. It houses capabilities for 5 million lyophilized vials per month, 6 million liquid vials per month, and 10 million ampoules per month. The company has received 203 State FDA approvals to date. In Q4 FY26, the company executed GLP-1 validation batches for a big pharma client and commenced the migration of CMO clients from the Navsari Unit-2 to Indore.

International Business

Gufic Biosciences is shifting its international business model from a distributor-led approach to an IP-owned, complex-injectable-led market access model. Gufic Ireland secured its first Marketing Authorization in the EU, providing direct access to EU markets. The company filed 2 products in 18 EU countries in the current quarter. Additionally, 24 key product and facility approvals were secured across South Africa, Colombia, Portugal, Myanmar, Sri Lanka, Cambodia, Thailand, and Lithuania in H1.

Gufic Biosciences Limited has approved a further investment of ₹5.75 crore in Saraswat Co-operative Bank Limited to strengthen its existing banking relationship and support its treasury management strategy. The Board of Directors approved the subscription to 57,50,800 equity shares at a face value of ₹10 each during a meeting held on May 29, 2026. This strategic investment is expected to enhance the company's banking engagement and provide potential long-term benefits through investment appreciation and dividend income.

The transaction does not fall under related party transactions, and the promoter or promoter group has no interest in the acquisition. The company currently holds 7,500 equity shares in the bank, which will increase to 57,58,300 shares post-acquisition. The consideration for the acquisition will be paid in cash, and the entire process is slated for completion within four months.

Saraswat Co-operative Bank, incorporated in 1918, operates as a scheduled bank offering a suite of banking and financial services, including retail and wholesale banking and treasury operations. As of March 31, 2025, the bank reported a total income of ₹5064.53 crore and a net worth of ₹5484.91 crore. The bank's total subscribed capital stands at 32,01,75,196 shares of ₹10 each.

The investment aligns with Gufic Biosciences' regular utilisation of banking and credit facilities from Saraswat Bank for its business operations and expansion requirements. The company stated that the subscription to additional equity shares is in line with its existing credit exposure and broader investment strategy.

Financials of Saraswat Co-operative Bank